Search
ruxolitinib (Jakafi, Opzelura)
Indications:
- 1st FDA-approved drug for treatment of myelofibrosis
- polycythemia vera
- atopic dermatitis (topical) [2]
- vitiligo (Opzelura, topical FDA-approved)* [3]
- glucocorticoid-refractory chronic graft-versus-host disease [4]
* after 2 years, 84% with > 50% improvement in facial vitiligo, 52% with 90% improvement [3]
Dosage:
- 10 mg PO BID [4]
- topical (Opzelura) BID
Tabs: 5, 10, 15, 20, 25 mg
Cream: 1.5%
Adverse effects:
- thrombocytopenia
- anemia
- fatigue
- diarrhea
- dyspnea
- headache
- dizziness
- nausea
- confusion
Mechanism of action:
- inhibits JAK1 & JAK2
- reduces myelofibrosis-related symptoms, including splenomegaly, abdominal pain, night sweats, bone or muscle pain, itching
Specific
Ruxolitinib Topical
General
small inhibitory antineoplastic agent (ib drug)
enzyme inhibitor
Database Correlations
PUBCHEM correlations
References
- Chestecka Z
Medscape Oncology, 11/16/2011
FDA Approves Ruxolitinib, First Drug Ever for Myelofibrosis
http://www.medscape.com/viewarticle/753682
- Kim BS, Howell MD, Sun K et al.
Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor)
or triamcinolone cream.
J Allergy Clin Immunol 2020 Feb; 145:572.
PMID: 31629805 Free Article
https://www.jacionline.org/article/S0091-6749(19)31326-0/fulltext
- Bankhead C
Topical JAK Inhibitor Shows Promise in Vitiligo.
Half of patients had 90% improvement after 2 years of treatment.
MedPage Today April 30, 2021
https://www.medpagetoday.com/meetingcoverage/aad/92371
- Forand RL
FDA approves Opzelura cream for vitiligo.
Healio. Dermatology. July 19, 2022
https://www.healio.com/news/dermatology/20220719/fda-approves-opzelura-cream-for-vitiligo
- Harris JE, et al
Safety and efficacy of ruxolitinib cream for the treatment of vitiligo:
104-week data from a phase II study.
American Academy of Dermatology (AAD) 2021; Poster 27535.
https://www.medpagetoday.com/meetingcoverage/aad/92371
- Pandya AG, et al
Addition of narrow-band ultraviolet B phototherapy to ruxolitinib cream
in patients with vitiligo.
American Academy of Dermatology (AAD) 2021; Poster 27636.
- Zeiser R, Polverelli N, Ram R et al
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
N Engl J Med 2021; 385:228-238. July 15.
PMID: 34260836
https://www.nejm.org/doi/full/10.1056/NEJMoa2033122